Amisulpride in Schizophrenic Patients

Inclusion Criteria: * Patients diagnosed as schizophrenia or schizophrenic disorder according to DSM-IV * Patients who need new anti-psychotic drugs or need to change the medication due to aggravations of symptoms or recurrence Exclusion Criteria: * Patients with positive symptoms in whom the disorder does not correspond to schizophrenic criteria. (e.g, schizoaffective disorder) * Patients hypersensitive to the active ingredient or to other ingredients of the study drug * Prolactin-dependant tumors, pituitary gland prolactinomas and breast cancer * Pheochromocytoma or Parkinson's disease * Pregnancy or breast feeding * Current or recently withdrawn from drug abuse or alcoholism * Chronic renal failure and other internal or surgical disease which physician decides will be worsened by trial medication or that will affect the metabolism or effects of the trial medication * Patients with previous histories and clinical improvement was not seen in spite of treatment with 2 anti-psychotics for over 8 weeks * Slow heart rate of \<55bpm, low blood potassium level, congenital prolongation of the QT interval * Current treatment with a drug likely to cause markedly slow heart rate(\<55bpm), low blood potassium level, slowing of intercardiac condition or prolongation of the QT interval The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.